Sanofi Pasteur and KaloBios in Pa agreement
Sanofi Pasteur, the vaccines division of French drugmaker Sanofi Aventis, has agreed with US biotech KaloBios Pharmaceuticals to develop a Humaneered antibody fragment to treat Pseudomonas aeruginosa (Pa) infections.
Sanofi Pasteur, the vaccines division of French drugmaker Sanofi Aventis, has agreed with US biotech KaloBios Pharmaceuticals to develop a Humaneered antibody fragment to treat Pseudomonas aeruginosa (Pa) infections.
Under the terms of the agreement, Sanofi Pasteur acquires worldwide rights to KaloBios" technology for all disease indications related to Pa infections, except cystic fibrosis and bronchiectasis, which Sanofi Pasteur has the option to obtain at a later date.
KaloBios has already completed phase I clinical trials and a small proof of concept phase II clinical trial in mechanically ventilated patients.
"KaloBios has shown convincing safety data in phase I studies and a trend toward efficacy in a phase II study of ventilator-associated pneumonia," said Wayne Pisano, president and ceo of Sanofi Pasteur.
The two primary target indications for the antibody are prevention of Pa associated pneumonia in mechanically ventilated patients in hospitals as well as prevention of relapses and potential improvement of treatment outcomes in patients with an ongoing Pa infection.